A real-world data analysis of the risk of stroke or systemic embolism and rate of major bleeding among patients with non-valvular atrial fibrillation who were treated with direct oral anticoagulants versus warfarin

Trial Profile

A real-world data analysis of the risk of stroke or systemic embolism and rate of major bleeding among patients with non-valvular atrial fibrillation who were treated with direct oral anticoagulants versus warfarin

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin
  • Indications Embolism; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 22 Mar 2017 New trial record
    • 17 Mar 2017 Results published in a Bristol-Myers Squibb media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top